• 1. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 2. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 3. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives 2-halopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Halopyridines 2-halopyridines

Research Brief on 2-Chloropyridine-4-sulfonyl chloride (CAS: 1000933-25-4) in Chemical Biology and Pharmaceutical Applications

2-Chloropyridine-4-sulfonyl chloride (CAS: 1000933-25-4) is a key intermediate in the synthesis of biologically active compounds, particularly in the development of sulfonamide-based pharmaceuticals. Recent studies have highlighted its utility in medicinal chemistry, where it serves as a versatile building block for the design of enzyme inhibitors, receptor antagonists, and other therapeutic agents. This research brief consolidates the latest findings on the applications, synthetic methodologies, and mechanistic insights related to this compound, providing a comprehensive overview for researchers in the field.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of 2-Chloropyridine-4-sulfonyl chloride in the synthesis of novel sulfonamide derivatives targeting carbonic anhydrase isoforms. The study reported significant inhibitory activity against tumor-associated CA-IX and CA-XII, suggesting potential applications in cancer therapy. The compound's reactivity with primary and secondary amines was leveraged to generate a library of derivatives, with several candidates showing nanomolar affinity in enzymatic assays.

In the realm of antimicrobial drug development, researchers at the University of Cambridge (2024) utilized 2-Chloropyridine-4-sulfonyl chloride as a key intermediate for creating sulfonylhydrazone derivatives with potent activity against multidrug-resistant Gram-positive pathogens. The structural flexibility afforded by the chloropyridine moiety allowed for optimal positioning of pharmacophores, resulting in compounds with improved membrane penetration and target binding.

Recent advances in synthetic methodology have expanded the utility of 2-Chloropyridine-4-sulfonyl chloride. A 2024 Organic Letters publication detailed a novel continuous flow chemistry approach that improves the safety and scalability of sulfonylation reactions using this reagent. The method achieved 92% yield with minimal byproduct formation, addressing previous challenges associated with exothermic reactions and chloride byproduct accumulation.

Mechanistic studies have provided deeper insights into the reactivity profile of 2-Chloropyridine-4-sulfonyl chloride. Density functional theory (DFT) calculations published in Chemical Science (2023) revealed that the electron-withdrawing effect of the sulfonyl chloride group activates the 2-position chlorine for nucleophilic aromatic substitution, while the 4-position remains available for subsequent derivatization. This dual reactivity makes the compound particularly valuable for sequential functionalization strategies.

The pharmaceutical industry has shown increasing interest in this compound, with recent patent filings (2023-2024) disclosing its use in PROTAC (proteolysis targeting chimera) development. The chloropyridine-sulfonyl moiety serves as an effective linker between target-binding and E3 ligase-recruiting components, enabling the creation of selective protein degraders with improved pharmacokinetic properties.

Analytical characterization of 2-Chloropyridine-4-sulfonyl chloride has also seen advancements. A 2024 Journal of Pharmaceutical and Biomedical Analysis paper presented a validated HPLC method for purity assessment, crucial for ensuring batch-to-batch consistency in pharmaceutical applications. The method demonstrated excellent linearity (R2 > 0.999) across a concentration range of 0.1-10 mg/mL.

Looking forward, researchers anticipate expanded applications of 2-Chloropyridine-4-sulfonyl chloride in covalent inhibitor design, particularly for targeting cysteine residues in disease-relevant proteins. Preliminary results from a 2024 ACS Medicinal Chemistry Letters report suggest that the compound's sulfonyl chloride group can be strategically employed for irreversible inhibition while maintaining selectivity through the pyridine scaffold's directional interactions.

• 6684-06-6(2-Chloro-pyridine-3-sulfonyl Chloride)
• 239810-43-6(2,6-Dichloropyridine-3-sulfonyl chloride)
• 141519-77-9(1-Chloro-5-isoquinolinesulfonyl Chloride)
• 750583-88-1(3-Pyridinesulfonyl chloride, 6-chloro-, hydrochloride)
• 6684-39-5(6-Chloropyridine-3-sulfonyl Chloride)
• 105627-81-4(5-Isoquinolinesulfonyl chloride, 1-chloro-, hydrochloride)
• 205055-71-6(2-Chloroquinoline-6-sulfonyl Chloride)
• 223671-80-5(1,4-Dichloro-7-isoquinolinesulfonyl Chloride)
• 489430-50-4(Pyridine-4-sulfonyl chloride hydrochloride)
• 134479-04-2(Pyridine-4-sulfonyl chloride)